Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

The American healthcare provider Molina Healthcare finds itself navigating the most severe turbulence in its recent history. A disastrous quarterly performance and substantial guidance reduction have triggered a wave of class-action lawsuits. Yet, in a surprising twist, a famous investor appears to be spotting a potential opportunity. Is the company on the verge of a turnaround, or is it teetering on the edge of a precipice?

A Legendary Contrarian Bet

Amidst the severe sell-off, a significant development has captured market attention. Michael Burry, the investor famed for his role in “The Big Short,” established a new position in Molina Healthcare during the third quarter. This contrarian move comes at a time when the stock has plummeted by more than 50% since the start of the year and is trading near its 52-week low. The critical question for investors is whether Burry has identified value that the broader market is overlooking. The company’s core Medicaid business, which accounts for a stable 75% of premium revenue, provides a solid foundation. Furthermore, Molina Healthcare is projecting premium revenue of approximately $46 billion for 2026, driven by new contracts in states including Georgia and Texas.

Legal Onslaught Follows Earnings Collapse

The catalyst for the current crisis was the company’s quarterly report released on October 22. The figures revealed a stark reality: instead of the anticipated $3.97, Molina Healthcare achieved only $1.84 in adjusted earnings per share. Even more dramatic was the slashing of its full-year 2025 guidance, which was revised down from an initial $24.50 to “not less than $19,” and finally to just $14.

Should investors sell immediately? Or is it worth buying Molina Healthcare?

In the wake of this disclosure, multiple law firms filed class-action lawsuits against the company between November 3 and November 5. The allegations are severe, claiming that between February and July 2025, Molina Healthcare knowingly issued misleading statements concerning its medical cost projections. Investors accuse the leadership of concealing the true extent of the company’s challenges until the disappointing results were made public.

The Path to Recovery

In response, management has announced a decisive action plan. This includes a significant reduction in market presence, with the company exiting approximately 20% of its counties and securing average rate increases of 30%. There are preliminary indications that state Medicaid rates for the coming year might slightly exceed medical costs, which could lay the groundwork for the margin recovery the company is targeting.

However, the path forward remains clouded with uncertainty. The deadline for the class-action lawsuits is December 2, 2025, and the next quarterly report in early 2026 will be a critical test to see if the new strategic direction is yielding results. With the stock technically hovering near its lows, the market is left to ponder a fundamental question: Is the prevailing sentiment driven by justifiable fear, or has Michael Burry once again demonstrated his famed foresight?